Last reviewed · How we verify
Propoxyphene Compound 65 (PROPOXYPHENE)
Propoxyphene Compound 65, also known as PROPOXYPHENE, is a small molecule opioid agonist that targets the glutamate receptor ionotropic, NMDA 3A. Originally developed in 1957, it is used to treat pain and is currently off-patent with 21 generic manufacturers. As an opioid agonist, it works by binding to opioid receptors in the brain, leading to pain relief. However, its commercial status and safety considerations are not well-documented due to the lack of information on its bioavailability and half-life.
At a glance
| Generic name | PROPOXYPHENE |
|---|---|
| Drug class | Opioid Agonist |
| Target | Glutamate receptor ionotropic, NMDA 3A |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
- Pain
Common side effects
Drug interactions
- rasagiline
- ritonavir
- selegiline
- sodium oxybate
- tranylcypromine
Key clinical trials
- Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions (PHASE2,PHASE3)
- Lumbar Stenosis Outcomes Research II (PHASE4)
- Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain (PHASE4)
- Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propoxyphene Compound 65 CI brief — competitive landscape report
- Propoxyphene Compound 65 updates RSS · CI watch RSS